Abstract. Erlotinib is an inhibitor of the tyrosine-kinase domain of the epidermal growth factor receptor-1 (EGFR). This drug is used to treat some solid cancers, particularly advanced non-small-cell lung carcinoma. Similar to other EGFR inhibitors, erlotinib is responsible for a series of skin adverse reactions, particularly acneiform lesions. We described the incidental effect of erlotinib on actinic keratoses which became markedly inflamed and showed partial regression. Inflammation appeared to spontaneously decrease while on erlotinib treatment. This reaction in the skin neoplasm is perhaps a visible and accessible model for predicting the effect in the deep-seated neoplasm targeted by the drug.

1. Introduction

Erlotinib (Tarceva®, Roche Pharma) is a small molecule inhibiting the tyrosine-kinase activity of the EGF receptor (EGFR). The EGFR family is part of a complex signal-transduction network that is central to several critical cellular processes (1). The human EGFR family is disregulated in many solid tumors, making it an attractive target for anticancer therapy. Erlotinib specifically binds to the cytoplasmic domain of the EGFR and has been approved in recent years for chemotherapy-resistant non-small-cell lung carcinoma (NSCLC) (2-6). This drug is also employed for the treatment of a few other solid tumors (7).

Treatments with erlotinib, and other EGFR inhibitors as well, are frequently responsible for cutaneous adverse effects. These unwanted reactions are quite typical for this drug family, and distinct from the skin adverse effects related to other types of anti-cancer chemotherapy (8). The most frequent skin manifestation following anti-EGFR treatment consists of an acneiform pustular eruption (9-11). Other dermatologic reactions include paronychia and some nail changes, abnormalities in hair growth, xerosis, hypersensitivity reactions, non-specific maculopapular rashes, stomatitis, mucositis and pruritus (9-11). One case report described the incidental development of inflammation of previously undetected actinic keratoses while on sorafenib therapy (12). We presently report the self-limited inflammatory flare-up of actinic keratoses during erlotinib treatment. To the best of our knowledge, this condition has never been reported as a complication of erlotinib treatment.

2. Actinic keratoses and squamous cell carcinomas

Chronically sun-exposed skin of the face is susceptible to develop actinic keratoses which are at risk to evolve into squamous cell carcinomas (13-15). These lesions are increasingly recognized in individuals at the age when internal cancers are also prevalent (16,17).

There are many methods for treating actinic keratoses (18). Physical procedures for destroying the lesions are commonly used. Some specific topical drugs are also employed. Among them, imiquimod and 5-fluorouracil have proven their efficacy (19). Inflammation is typically present during their regression phase (20,21), but also conversely during progression of actinic keratoses to squamous cell carcinomas (22).

Other conventional chemotherapeutic agents which have been associated with the inflammation of actinic keratosis include docetaxel, doxorubicin, capetistibamine, pentostatin, sorafenib and the combination of daetinoximycin, vincristine, dacarbazine and doxorubicin, cytarabine and 6-thioguanine (8,12,23,24). The mechanism by which these agents lead to this effect is unknown, although abnormal DNA synthesis and a form of radiation recall have been postulated (12).

3. Erlotinib and actinic keratoses

The effect of erlotinib on actinic keratoses was first documented as an incidental finding in a 77-year-old man treated for a cisplatin-resistant NSCLC. This phototype 2 patient had also been previously treated for several actinic keratoses and basal cell carcinomas developed on photo-exposed areas. The actinic keratoses which were not responsive to topical 5-fluorouracil were destroyed by electrocoagulation. In addition, a total of 28 basal cell carcinomas were surgically excised over a period of years and were submitted for histopathologic confirmation.

Two years ago, the patient was diagnosed with a T2 N1 M0 NSCLC and treated by lobar excision and radiotherapy. One year later, abdominal metastases developed. They were first treated with cisplatin chemotherapy without any obvious clinical response. Recently, a therapy of 150 mg/day erlotinib (Tarceva) was initiated.
At day 10 of erlotinib treatment, itchy pustules appeared on the face, trunk and limbs (Figs. 1 and 2). Crusts formed on the scalp and a xerotic dermatitis developed mainly on the arms. These manifestations corresponded to the typical adverse effects of erlotinib. They were treated with limecycline, 300 mg x 2/day, benzoyl peroxide gel on the face and mometasone furoate solution on the scalp. Treatment with
erlotinib was continued. A marked improvement of the pustular eruption and of the squamous dermatitis of the scalp was observed after approximately three weeks.

Upon examination 10 days after starting erlotinib treatment, inflammatory changes were present at the site of the actinic keratoses on the face (Fig. 3). They led to squame-crust formation underlined by superficial necrosis of the epithelial tumors (Fig. 4). After clearing away the necrotic debris, healing was observed. A biopsy was taken at day 20 of erlotinib treatment. The microscopic examination showed the typical epidermal characteristics of actinic keratosis/in situ squamous cell carcinoma (Fig. 5a). The density of the lymphoid cell infiltrate was quite extensive. The epidermal neoplasm was focally infiltrated and dissociated by the inflammatory cells. At these sites, there were discrete signs of neoplastic regression and partial destruction (Fig. 5b). Two months later, the skin lesions were unchanged (Fig. 6) but the general status of the patient was progressively altered.

Since that initial case of inflammatory actinic keratoses while on erlotinib treatment, a few other cases were observed by our staff members. However, these cases are too few to allow any assessment of the incidence of this condition.

4. EGFR inhibitors and inflamed actinic keratosis in perspective

There is a conceptual controversy regarding actinic keratosis as a precursor of, or as an already in situ squamous cell carcinoma (16,25-27). It is also uncertain whether to interpret inflammation of actinic keratosis as a sign of neoplastic progression or regression (22). In any case the severity of the histological grading of the neoplasm is important to consider. Indeed, any inflammatory change in incipient or superficial actinic keratosis is of little importance in the short term because the risk of dermal invasion and distant metastasis is minimal or absent. By contrast, the thicker lesions ready to evolve into a full-blown squamous cell carcinoma are more problematic. Tragically, the few months of survival time expected of the patients undergoing anti-EGFR therapy for a metastatic NSCLC will likely not be affected by any progression of actinic keratoses.

More importantly, the effect of erlotinib on actinic keratoses and in situ squamous cell carcinoma might be regarded as a model in the understanding of the drug's effect on internal carcinomas including NSCLC. The reactions at these skin sites might possibly be better correlated with the efficacy of the drug on the target neoplasm than with any other cutaneous sign (28,29). In this condition, the role of the inflammatory cell infiltrate is probably similar to that of a bystander. Indeed, the drug is expected to exert a primary effect on the neoplastic cells themselves. The inflammatory cell reaction is limited to a secondary reactive process to the neoplastic damages. This condition would therefore be different from the usual immune response mounted against neoplasms and occasionally inducing a partial or total regression.

5. Conclusion

We reported an undescribed adverse effect of erlotinib at the site of actinic keratoses. The lesions became inflamed and showed partial regression. We did not encounter a complete clearing of these tumors.

References


